Identifying Strategies to Improve Shared Decision Making for Pregnant Patients’ Decisions about Prenatal Genetic Screens and Diagnostic Tests
- 31 July 2024
- journal article
- research article
- Published by SAGE Publications in Medical Decision Making
- Vol. 44 (6) , 689-704
Abstract
Purpose: Prenatal genetic screens and diagnostic tests are vital components of prenatal care. The first prenatal visit is a critical time in the decision-making process when patients decide whether to use these tests in addition to address a series of other essential prenatal care aspects. We conducted this study to examine the role of a shared decision-making (SDM) instrument to support these discussions. Methods: We conducted a cluster randomized controlled trial of patients allocated to an SDM tool or usual care at their first prenatal visit. Participants completed a baseline survey to measure decision-making needs and preferences. Direct observation was conducted and analyzed using the OPTION scale to measure SDM during prenatal genetic testing discussions. Results: Levels of SDM were similar across groups ( P = 0.081). The highest levels of SDM were observed during screening test discussions (NEST 2.4 ± 0.9 v. control 2.6 ± 1.0). Lowest levels were observed in discussions about patients’ preference for risk versus diagnostic information (NEST 1.0 ± 1.1 v. control 1.2 ± 1.3). Conclusion: Study findings demonstrate the need for targeted patient-focused and provider-focused efforts to improve SDM to enhance patients’ informed decision making about these options. Importantly, patients’ baseline knowledge and attitudes need to be considered given that patients with less knowledge may need more carefully crafted communication. Highlights: Choices about whether, when, and how to use prenatal genetic tests are highly preference-based decisions, with patients’ baseline attitudes about these options as a major driver in health care discussions. The decision-making process is also shaped by patient preferences regarding a shared or informed decision-making process for medical decisions that are highly personal and have significant ramifications for obstetric outcomes. There is a need to develop targeted efforts to improve decision making and enhance patients’ ability to make informed decisions about prenatal genetic tests in early pregnancy.Keywords
Funding Information
- National Human Genome Research Institute (R01HG010092)
This publication has 48 references indexed in Scilit:
- Making the most of the first prenatal visit: The challenge of expanding prenatal genetic testing options and limited clinical encounter timePrenatal Diagnosis, 2020
- The personal utility of cfDNA screening: Pregnant patients' experiences with cfDNA screening and views on expanded cfDNA panelsJournal of Genetic Counseling, 2019
- High risk—What's next? A survey study on decisional conflict, regret, and satisfaction among high‐risk pregnant women making choices about further prenatal testing for fetal aneuploidyPrenatal Diagnosis, 2019
- The impact of non‐invasive prenatal testing on anxiety in women considered at high or low risk for aneuploidy after combined first trimester screeningPrenatal Diagnosis, 2017
- Informed choice and decision making in women offered cell‐free DNA prenatal genetic screeningPrenatal Diagnosis, 2016
- A qualitative study looking at informed choice in the context of non‐invasive prenatal testing for aneuploidyPrenatal Diagnosis, 2016
- Encouraging Patients to Ask QuestionsJAMA, 2013
- Noninvasive prenatal testing: the paradigm is shifting rapidlyPrenatal Diagnosis, 2013
- Best ethical practices for clinicians and laboratories in the provision of noninvasive prenatal testingPrenatal Diagnosis, 2013
- Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic lociPrenatal Diagnosis, 2012